A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 24 Aug 2017 Status changed from recruiting to completed.
- 27 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Apr 2012 Actual initiation date (Dec 2011) added as reported by ClinicalTrials.gov.